You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

ZERVIATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zerviate patents expire, and what generic alternatives are available?

Zerviate is a drug marketed by Harrow Eye and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-three patent family members in seven countries.

The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-four suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zerviate

A generic version of ZERVIATE was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZERVIATE?
  • What are the global sales for ZERVIATE?
  • What is Average Wholesale Price for ZERVIATE?
Summary for ZERVIATE
Drug patent expirations by year for ZERVIATE
Drug Prices for ZERVIATE

See drug prices for ZERVIATE

Pharmacology for ZERVIATE

US Patents and Regulatory Information for ZERVIATE

ZERVIATE is protected by four US patents.

Patents protecting ZERVIATE

Ophthalmic formulations of cetirizine and methods of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Ophthalmic formulations of cetirizine and methods of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Ophthalmic formulations of cetirizine and methods of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Ophthalmic formulations of cetirizine and methods of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Harrow Eye ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Harrow Eye ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Harrow Eye ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Harrow Eye ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZERVIATE

See the table below for patents covering ZERVIATE around the world.

Country Patent Number Title Estimated Expiration
Mexico 2011009802 FORMULACIONES OFTALMICAS DE CETIRIZINA Y METODOS DE USO. (OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE.) ⤷  Sign Up
Japan 2013522312 ⤷  Sign Up
European Patent Office 3943069 FORMULATIONS OPHTALMIQUESDE CETIRIZINE ET PROCEDES D'UTILISATION (OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE) ⤷  Sign Up
Japan 2012520882 ⤷  Sign Up
Japan 6033677 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZERVIATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0058146 2001C/045 Belgium ⤷  Sign Up PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828 C300085 Netherlands ⤷  Sign Up PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.